ArticleNeuro-oncology advances
A deep learning algorithm for fully automated volumetric measurement of meningioma burden.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Convolutional neural networks: applications, challenges and future prospects in brain tumor research.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We sought to develop a deep learning (DL) model to enable fully automated 3D segmentation and volumetric assessment of meningioma burden with a specific emphasis on generalizing to high-grade and posttreatment meningiomas to improve interobserver variability and decrease reader time investment in tumor response assessment. Methods: In total, 450 postcontrast T1-weighted brain MRIs from 104 patients with meningiomas were obtained from Massachusetts General Hospital and Dana-Farber Cancer Institute. The cohort was unique among prior DL segmentation models in that it encompassed meningiomas of all grades, postoperative, and postradiated meningiomas. Preprocessed MRIs and manually generated tumor segmentations were used to train a U-Net with a joint Dice-cross entropy loss function. Results: When tested on internal data, our model achieved a median Dice of 0.741 and a median 95th percentile Hausdorff Distance (HD95) of 26 mm on a high-grade test set and a median Dice of 0.848 and median HD95 of 1.41 mm on a test set with low-grade tumors. Lesion-wise metrics were equivalent to global metrics for low-grade tumors, which contained only single lesions, but were substantially lower for high-grade tumors, with a median lesion-wise Dice of 0.45 and median lesion-wise HD95 of 130 mm, reflecting greater difficulty delineating individual high-grade lesions. Our model also generalized well to 1000 studies from 944 patients selected from the public BraTS dataset, achieving a median Dice of 0.923 and median HD95 of 2.24 mm. Conclusions: The study produced a model that addresses an unmet need for automated volumetric measurements of meningiomas and created a reliable metric for quantifying meningioma burden. In comparison to prior DL approaches, our model achieved competitive performance on external data and improved Dice scores on high-grade and posttreatment meningiomas. The trained model, volumetric evaluation code, and accompanying documentation are available online at https://github.com/mccle/tumor_segmentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.